Rapid Micro Biosystems FY2021 commercial revenue up 54% to $21.6M; net loss $73.5M

RAPID MICRO BIOSYSTEMS, INC.

FY2021 total revenue $23.2M vs $16.1M; commercial revenue $21.6M (+54%); net loss $73.5M vs $37.1M.
Q4 2021 total revenue $5.2M flat YoY; commercial revenue $4.9M; recurring revenue $2.3M (+91%).
FY2022 commercial revenue guidance reaffirmed at $27M-$32M (25-50% growth).
Cash, cash equivalents and investments $203.5M, no debt.
Placed 29 new systems FY2021; cumulative placed 116, validated 84.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.